Onco-Innovations CEO Highlights Strategic Milestones and R&D Progress in Special Investors' Conference Call

Rhea-AI Summary

Onco-Innovations (OTCQB:ONNVF) CEO Thomas O'Shaughnessy provided a comprehensive update on the company's strategic developments and R&D progress during a special investor call. Key highlights include the advancement of their PNKP Inhibitor Technology with Dalton Pharma Services for preclinical testing, and progress in the PROmAI consortium with potential AstraZeneca participation.

The company has established a new research agreement with the University of Alberta and Cross Cancer Institute to study PNKP inhibition in glioblastoma multiforme. Following their February 2025 acquisition of Inka Health AI and May 2025 uplisting to Cboe Canada, Onco-Innovations continues to integrate AI capabilities into drug development through Inka's Synograph system.

Positive

• None.

Negative

• Clinical trials yet to begin with key regulatory milestones pushed to 2026
• Still in early-stage research phase without clinical validation

VANCOUVER, BC / ACCESS Newswire / July 2, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that on July 2, 2025, its Chief Executive Officer, Thomas O'Shaughnessy, held an investor call during which he provided shareholders with an update on the Company's strategic milestones and development roadmap, as it continues to advance its mission to accelerate cancer treatment innovation through cutting-edge therapeutics and artificial intelligence.

The update overviewed significant advancements in the Company's Research and Development efforts, particularly the continued development of its lead Polynucleotide Kinase 3'-Phosphatase (PNKP) Inhibitor Technology. Mr. O'Shaughnessy spoke to Onco's engagement of Dalton Pharma Services to initiate manufacturing activities for preclinical testing material, reiterating that this marks the beginning of the transition from early-stage research to scaled production and clinical preparation.

Mr. O'Shaughnessy then outlined the near-term focus areas of the Company's R&D roadmap, including the selection of contract research partners, the commencement of GLP preclinical testing, and preliminary preparation efforts towards eventual Phase 1 clinical trials. He emphasized that these activities are critical to achieving key regulatory milestones in 2026, which are part of a global multi-region clinical development plan.

As part of this AI-focused strategy, Mr. O'Shaughnessy provided an update on the PROmAI consortium, a strategic initiative led by Inka Health AI and designed to bring together global pharmaceutical partners and scientific experts. The consortium's goal is to support the development of causal AI tools that improve predictive modeling and regulatory alignment in oncology drug development. He confirmed that AstraZeneca has expressed interest in participating as a founding member, which underscores the consortium's relevance to the broader industry.

Further supporting this development pipeline, Onco recently entered into a new research agreement with the University of Alberta and the Cross Cancer Institute. Mr. O'Shaughnessy explained that this collaboration will explore the application of PNKP inhibition in glioblastoma multiforme (GBM), one of the most treatment-resistant forms of cancer. The preclinical study is expected to generate data that could lay the groundwork for future combination treatment strategies and expanded indications.

Mr. O'Shaughnessy highlighted Onco-Innovations' continued corporate momentum, including the Company's recent uplisting to Cboe Canada Inc. on May 22, 2025. He described the listing as a meaningful step toward expanding capital market visibility, strengthening investor engagement, and aligning capital strategy with the Company's long-term scientific goals.

He also reflected on the Company's acquisition of Inka Health AI in February 2025, a move that strategically positions Onco to integrate artificial intelligence into its drug development efforts. Inka Health brings advanced capabilities in real-world data analytics and AI model development, supported by a distinguished scientific team. Mr. O'Shaughnessy noted that this acquisition plays a critical role in enhancing R&D performance and strengthening the Company's ability to drive precision oncology forward.

Finally, Mr. O'Shaughnessy reaffirmed Onco-Innovations' commitment to uniting novel drug development with advanced artificial intelligence platforms, such as Inka Health's proprietary Synograph system. He noted that further updates would be shared soon regarding Synograph's evolution and its growing role in strategic partnerships and AI-driven research.

The Company looks forward to continuing its mission to bring forward a new class of therapies for solid tumors, accelerated by AI, and to share further updates on its progress toward clinical translation in the months ahead.

About Inka Health

Inka Health is an AI-driven analytics company revolutionizing oncology research and drug development through advanced causal AI. Its proprietary platform, SynoGraph, leverages AI-powered causal inference to identify which cancer patients are most likely to respond to specific treatments, advancing precision medicine. By integrating diverse multimodal medical data-including genomics, transcriptomics, and proteomics-SynoGraph uncovers hidden insights that can optimize treatment decisions and clinical trial design. With this cutting-edge technology, Inka Health aims to help pharmaceutical companies accelerate drug development, reduce trial failures, and bring life-saving therapies to market faster.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

"Thomas O'Shaughnessy"
Chief Executive Officer

For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com

Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

SOURCE: Onco-Innovations Limited

View the original press release on ACCESS Newswire

FAQ

What major developments did Onco-Innovations (ONNVF) announce in their July 2025 investor call?

CEO Thomas O'Shaughnessy announced progress in PNKP Inhibitor Technology development, partnership with Dalton Pharma Services, potential AstraZeneca collaboration in PROmAI consortium, and a new research agreement with University of Alberta for glioblastoma treatment.

When did Onco-Innovations acquire Inka Health AI and what is its significance?

Onco-Innovations acquired Inka Health AI in February 2025 to integrate artificial intelligence into drug development efforts, bringing advanced capabilities in real-world data analytics and AI model development through their proprietary Synograph system.

What is the timeline for Onco-Innovations' clinical trials and regulatory milestones?

The company is preparing for GLP preclinical testing and Phase 1 clinical trials, with key regulatory milestones targeted for 2026 as part of a global multi-region clinical development plan.

How will the University of Alberta partnership benefit Onco-Innovations' research?

The partnership will explore PNKP inhibition in glioblastoma multiforme (GBM), one of the most treatment-resistant cancers, potentially generating data for future combination treatment strategies and expanded indications.

What is the significance of Onco-Innovations' uplisting to Cboe Canada?

The uplisting to Cboe Canada on May 22, 2025 aims to expand capital market visibility, strengthen investor engagement, and align capital strategy with the company's long-term scientific goals.